Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL7796776 | 0.90 | FDPS (0.41) | FDPSBLMTDP1PPARDKDM4E | |
| Trolamine SCHEMBL3283288 | 0.87 | TDP1 (0.40) | FDPSBLMTDP1KDM4EMAPT | |
| Trolamine SCHEMBL2390784 | 0.85 | FDPS (0.39) | FDPSBLMTDP1KDM4EMAPT | |
| Trolamine SCHEMBL27412368 | 0.83 | MAPT (0.39) | KDM4EMAPTALOX15SMN1; SMN2 | |
| Trolamine SCHEMBL8884366 | 0.83 | MAPT (0.39) | KDM4EMAPTALOX15SMN1; SMN2 | |
| Trolamine SCHEMBL318178 | 0.83 | MAPT (0.39) | KDM4EMAPTALOX15SMN1; SMN2 | |
| Trolamine SCHEMBL5874691 | 0.83 | MAPT (0.39) | KDM4EMAPTALOX15SMN1; SMN2 | |
| Trolamine SCHEMBL7796775 | 0.83 | MAPT (0.39) | KDM4EMAPTALOX15SMN1; SMN2 | |
| Trolamine SCHEMBL28579666 | 0.83 | FDPS (0.35) | FDPSBLMTDP1KDM4EMAPT | |
| Trolamine SCHEMBL7564590 | 0.80 | MAPT (0.37) | KDM4EMAPTALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111087189-A | Hexavalent chromium reducing agent and preparation method thereof | 中国葛洲坝集团水泥有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-7858661-B2 | Protein refolding agent and refolding method | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100168403-A1 | Protein refolding agent and refolding method | YAMAGUCHI SHUNICHLRO | 2010-07-01 | — | — | US | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | FDPS 532/4885BLM 3232/4885TDP1 456/4885 |
| US-20100168403-A1 | Protein refolding agent and refolding method | HSPA5, HSPBP1, RRBP1 | FDPS 566/4885BLM 3143/4885TDP1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.